Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66
The financial markets received a much-needed breath of fresh air this week as the Bureau of Labor Statistics released the Producer Price Index (PPI) report for March 2026. Final demand prices rose by 0.5%, a figure that, while indicating growth, came in substantially lower than the 1.1% consensus
As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&A move in
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across the board. On April 14, 2026, the healthcare titan announced it was raising its full-year 2026 revenue and earnings guidance, signaling that
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning:
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
